Maintenance Notice (10:30 PM January 4 - 8:00 AM January 5, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.197 | Notice of Discontinuing the Use of Password-Protected Compressed Files | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
请选择数量
CAS RN: 877399-00-3 | 产品编码: B5682
(R)-5-Bromo-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine
产品编码 | B5682 |
纯度/分析方法 | >98.0%(HPLC) |
分子式/分子量 | C__1__3H__1__0BrCl__2FN__2O = 380.04 |
外观与形状(20°C) | 固体 |
储存温度 | 室温 (15°C以下阴凉干燥处) |
包装和容器 | 1G-Glass Bottle with Plastic Insert (查看图片) |
CAS RN | 877399-00-3 |
Reaxys-RN | 12134679 |
PubChem物质ID | 354335323 |
MDL编号 | MFCD18207061 |
技术规格
Appearance | White to Light yellow to Light orange powder to crystal |
Specific rotation(value) | -64.0 to -70.0 deg(C=1, CHCL3) |
Purity(HPLC) | min. 98.0 area% |
Purity(with Total Nitrogen) | min. 98.0 % |
Melting point | 108.0 to 113.0 °C |
物性(参考值)
熔点 | 109 °C |
比旋光度 [α]D | -67° (C=1,CHCl3) |
GHS
象形图 | |
信号词 | Warning |
危险性说明 | H315 : Causes skin irritation. H319 : Causes serious eye irritation. |
防范说明 | P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. |
相关法规
运输信息
HS编码* | 2933.39-000 |
应用
A Synthetic Intermediate of Tyrosine Kinase Inhibitors
This product has been used as a synthetic intermediate of tyrosine kinase inhibitors, such as crizotinib (PF-02341066).
References
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- Fit-for-Purpose Development of the Enabling Route to Crizotinib (PF-02341066)
- Synthesis of a Crizotinib Intermediate via Highly Efficient Catalytic Hydrogenation in Continuous Flow
应用
A Key Synthetic Intermediate of Crizotinib
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
References
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- Fit-for-Purpose Development of the Enabling Route to Crizotinib (PF-02341066)
参考文献